Sign in to view content

Brolucizumab for Neovascular AMD: The 2 Year HAWK and HARRIER Results

Pravin U. Dugel, MD

Video
Published 2018

Related

Open-Label Study Evaluating the Effects of the CCR3 Antagonist ALK4290 in Patients With Neovascular AMD Refractory to Anti-VEGF Therapy
Michael W. Stewart, MD
Annual Meeting Talks
2019
The Changing Avastin Landscape
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2019
Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies
David M. Brown, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more